TENAX THERAPEUTICS, INC. (TENX) - Dilution Analysis

10-Q filing | 26.5M shares outstanding

S-3 filing: Tenax Therapeutics, Inc. files an S-3 to offer and sell up to $300,000,000 of common stock, preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, or units consisting of a combination of any such securities.

10-K filing | 17.2M shares outstanding

10-Q filing | 6.2M shares outstanding

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.1M shares outstanding

S-3 filing: This S-3 filing describes a shelf offering for the resale of up to 4,139,072 shares of common stock, including shares and shares underlying pre-funded warrants, by selling stockholders.

10-K filing | 4.0M shares outstanding

8-K filing: Tenax Therapeutics, Inc. completed a private placement on March 5, 2025, issuing 378,346 shares of common stock and pre-funded warrants to purchase up to 3,760,726 shares, resulting in gross proceeds of approximately $25 million. ($47.69M proceeds)

10-Q filing | 3.4M shares outstanding

S-3 filing: This S-3 filing relates to the resale of common stock, shares of common stock issuable upon the exercise of pre-funded warrants, and shares of common stock issuable upon the exercise of warrants, all held by selling stockholders.

10-Q filing | 2.0M shares outstanding

8-K filing: Tenax Therapeutics, Inc. entered into a securities purchase agreement for a private placement with certain accredited investors, issuing 1,450,661 shares of common stock and pre-funded warrants to purchase up to 31,882,671 shares, along with warrants to purchase up to 16,666,666 shares, for gross proceeds of approximately $100 million. ($100.0M proceeds)

10-Q filing | 2.0M shares outstanding

POS AM filing: This prospectus relates to the offer and sale by Tenax Therapeutics, Inc. of up to 1,825 shares of our common stock underlying warrants previously issued by us to investors in a registered public offering that are issuable at an exercise price of $180.00 per share, as adjusted for our January 2024 reverse stock split.

POS AM filing: This POS AM filing details an offering of up to 3,200,000 shares of common stock issuable upon the exercise of outstanding warrants with an exercise price of $5.65 per share, with the warrants expiring on February 12, 2029. The company intends to use the net proceeds to initiate additional research sites and advance the enrollment and treatment of patients in the LEVEL trial, as well as for working capital, capital expenditures, and other general corporate purposes.

10-K filing | 2.0M shares outstanding

8-K filing: Tenax Therapeutics, Inc. closed a public offering on February 12, 2024, involving the sale of 421,260 shares of common stock and pre-funded warrants to purchase 1,178,740 shares, along with warrants to purchase up to 3,200,000 shares, resulting in gross proceeds of approximately $9.0 million. ($9.04M proceeds)

S-1/A filing: S-1/A filing for offering up to 960,000 shares of Common Stock on a 'best efforts' basis, each share being sold together with a warrant. Also offering pre-funded warrants to certain purchasers. The company estimates net proceeds of approximately $10.7 million.

S-1/A filing: Tenax Therapeutics, Inc. is offering shares of Common Stock and accompanying Warrants, as well as Pre-Funded Warrants in lieu of Common Stock for certain purchasers, with the net proceeds intended for working capital purposes and additional research sites.

8-K filing: Stock split 1-for-80 | Outstanding: 23,862,434 → 298,281

S-1 filing: This S-1 filing describes a best efforts public offering by Tenax Therapeutics, Inc., which includes common stock, warrants, and pre-funded warrants, with Roth Capital Partners, LLC acting as the exclusive placement agent. The company intends to use the net proceeds from this offering to initiate additional research sites and advance the enrollment and treatment of patients in the LEVEL trial, as well as for working capital, capital expenditures, and other general corporate purposes.

10-Q filing | 23.9M shares outstanding

10-Q filing | 23.9M shares outstanding

10-Q filing | 21.8M shares outstanding

10-K filing | 1.3M shares outstanding

8-K filing: Tenax Therapeutics, Inc. completed a public offering on February 7, 2023, selling 6,959,444 shares of common stock and pre-funded warrants to purchase 1,707,222 shares, along with accompanying warrants for 17,333,332 shares, at a combined price of $1.80 per share, resulting in gross proceeds of approximately $15.6 million. ($15.6M proceeds)

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock and warrants, with an option for purchasers exceeding a beneficial ownership limitation to purchase pre-funded warrants in lieu of common stock.

S-1 filing: Tenax Therapeutics, Inc. is conducting a best efforts public offering of common stock, warrants, and pre-funded warrants, with Roth Capital Partners, LLC acting as the exclusive placement agent.

10-Q filing | 25.2M shares outstanding

10-Q filing | 25.2M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 21,192,054 shares of common stock issuable upon exercise of Pre-Funded Warrants and Series E Warrants.

8-K filing: Tenax Therapeutics, Inc. completed a private placement offering on May 19, 2022, selling 10,596,027 units at $0.775 per unit for gross proceeds of approximately $8.0 million. ($8.0M proceeds)

10-Q filing | 25.2M shares outstanding

10-K filing | 25.2M shares outstanding

10-Q filing | 25.2M shares outstanding

S-3 filing: Tenax Therapeutics intends to use the net proceeds from the Offering to further its clinical trials of levosimendan and imatinib for research and development and for general corporate purposes, including working capital and potential acquisitions.

10-Q filing | 12.6M shares outstanding

10-Q filing | 15.0M shares outstanding

10-K filing | 12.6M shares outstanding

10-Q filing | 6.7M shares outstanding

S-3/A filing: The company agreed to issue shares of common stock and warrants in a registered direct offering and concurrent private placement, with aggregate gross proceeds of approximately $8.0 million, and common stock offered by selling stockholders.

S-3 filing: The company is issuing shares of common stock and warrants in a registered direct offering and private placement, with aggregate gross proceeds of approximately $8.0 million. Additionally, selling stockholders are offering 14,958,874 shares of common stock.

10-Q filing | 6.7M shares outstanding

10-Q filing | 9.2M shares outstanding

10-K filing | 6.7M shares outstanding